Antibody-Drug Conjugates (ADC): Next-Generation Targeted Cancer Therapy

Antibody-Drug Conjugates (ADC) represent a next-generation targeted cancer therapy technology that delivers potent anticancer agents directly to tumor cells. ADCs are composed of three main components: an antibody, a payload (drug), and a linker that connects the two. By combining an antibody with a cytotoxic drug, ADCs are engineered to selectively destroy cancer cells while minimizing damage to healthy tissue.

According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the global ADC market is projected to grow at a compound annual growth rate (CAGR) of 15.2%, expanding from $9.7 billion (approximately 12.6 trillion won) in 2023 to $19.8 billion (about 26 trillion won) by 2028.

Recently, attention has shifted to more advanced forms such as dual-antibody and dual-payload ADCs. Dual-antibody ADCs are designed so that a single antibody can simultaneously recognize two different antigens. Dual-payload ADCs combine two drugs with distinct mechanisms of action, enabling multi-faceted attacks on cancer cells and enhancing therapeutic efficacy.

(Seoul=Yonhap Infomax)

(End)

© Yonhap Infomax. All rights reserved. Unauthorized reproduction or redistribution, as well as AI training and utilization, are strictly prohibited.

All content has been translated by AI.
Copyright © Yonhap Infomax Unauthorized reproduction and redistribution prohibited.